PDB75 - COST-EFFECTIVENESS OF TREATING PATIENTS WITH TYPE 2 DIABETES POORLY CONTROLLED ON BASAL INSULIN WITH FIXED-RATIO COMBINATIONS OF BASAL INSULIN AND GLP-1 RECEPTOR AGONISTS IN DENMARK- IDEGLIRA VERSUS IGLARLIXI
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.780
https://www.valueinhealthjournal.com/article/S1098-3015(18)34080-4/fulltext
Section Title :
Section Order :
185
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34080-4&doi=10.1016/j.jval.2018.09.780